Value-Based Pricing

Value-Based Pricing: Linking a Medicine's Price to the Health It Adds

In health economics, value-based pricing means that the price a payer accepts for a medicine depends on how much health the medicine adds compared with the treatment it replaces, valued at the rate the health system can afford to pay for health. A medicine that adds more health can command a higher price, and the ceiling is the price above which buying it would displace more health elsewhere than it produces. This page covers the UK's planned 2014 reform and what replaced it, current UK practice under NICE and VPAG, benchmarks from the Institute for Clinical and Economic Review (ICER) in the United States, Sweden and Germany, the main criticisms, and a worked example showing how pricing rules share a medicine's value between manufacturer and health system.

From cost-based to value-based prices

Medicine prices have often been set from production cost, comparable products or prices abroad. In 2007 the UK Office of Fair Trading used the term value-based pricing for a system that would relate the prices of products to their clinical value relative to existing treatments. Value is incremental: the added health and the change in other costs against the comparator in use.

The economic argument rests on opportunity cost. With a fixed budget, extra spending on a new medicine displaces other care. If the health system can buy one quality-adjusted life year (QALY) elsewhere for a given sum, that sum is the cost-effectiveness threshold, and the value-based price is the price at which the medicine's health gain just offsets the health displaced by its extra cost. Claxton, Sculpher and Carroll describe this as the maximum transaction price the NHS can afford to pay for the benefits offered. At that price the net health benefit to the system is zero; a lower price leaves a net gain.

How a value-based price is derived

A value-based price is found by working backwards through a cost-effectiveness analysis. The modelled health gain and the change in other costs are fixed, and the drug price is solved so that the incremental cost per QALY equals the threshold. For one patient group:

$$P^{*} = k \times \Delta Q - \Delta C$$

where $P^{*}$ is the highest price per patient at which the medicine is just cost-effective, $k$ is the threshold in currency per QALY, $\Delta Q$ is the incremental QALYs per patient compared with current care, and $\Delta C$ is the incremental cost per patient of everything other than the new drug (negative when the drug saves costs elsewhere). The model-based search for this price is covered under threshold price and economically justifiable price.

Three inputs drive the answer. The threshold sets the exchange rate between money and health. The comparator determines $\Delta Q$ and $\Delta C$, so a weak comparator inflates the price. The population matters, because a medicine that works better in some patients than others has a different $P^{*}$ in each group.

The UK proposal for 2014 and what replaced it

According to the Parliamentary Office of Science and Technology (POST), the government stated its intention in May 2010 and the Department of Health consulted in December 2010. The proposal was that a higher cost per QALY could apply for medicines that tackled a high burden of illness, showed greater therapeutic innovation or brought wider societal benefits such as a return to work. Value-based pricing was planned to apply to new branded medicines from 2014.

The plan changed in stages. In March 2013 the government announced that NICE would take a central role. In June 2013 the Department confirmed a January 2014 start, and a month later it gave NICE terms of reference for what was called value-based assessment, because NICE would assess value and the Department would use the assessment in price negotiations. In November 2013 a new Pharmaceutical Price Regulation Scheme (PPRS) was agreed for January 2014 to December 2018. POST describes the PPRS as capping the profits companies can make from the NHS while leaving them free to set the price of individual drugs.

NICE's early 2014 proposals measured burden of illness and wider societal impact as proportional and absolute QALY shortfall, with a maximum combined weight of 2.5, which POST notes would cap the threshold at GBP 50,000 per QALY gained (GBP 20,000 × 2.5). More than 900 responses were published in September 2014, and the NICE Board found no agreement in them, so NICE's methods stayed as before. The same two shortfall measures now define the severity modifier in the NICE manual (PMG36), which allows QALY weights of 1.2 or 1.7 for more severe conditions.

The UK arrangement now: free launch prices, NICE thresholds and VPAG

The UK did not adopt an explicit value-based price-setting system. The idea operates instead through launch pricing rules, the NICE threshold and aggregate payments under VPAG.

Launch pricing. Under the 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG), new active substances have freedom of list pricing at launch, and the company confirms its intention to price at a level consistent with a positive NICE appraisal. Where the list price would not be cost-effective, a simple confidential discount through a patient access scheme remains the preferred route; wider deal types are covered under managed entry agreements.

The NICE threshold. NICE's range sets the effective ceiling on price. Following a government announcement of 1 December 2025, the range rose from GBP 20,000 to 30,000 per QALY to GBP 25,000 to 35,000 from April 2026, a change the VPAG document records.

Aggregate payments. VPAG, an agreement between the Department of Health and Social Care, NHS England and the Association of the British Pharmaceutical Industry, runs from 1 January 2024 to 31 December 2028. Companies pay a headline percentage of eligible sales of newer medicines, capped at 15% for 2026 to 2028. The percentage is derived from the gap between measured and allowed industry sales, so it controls total spending, not the price of any one product.

Value-based benchmarks outside the UK

Other systems apply the idea with different measures of value. Some publish benchmark prices, some tie reimbursement to cost-effectiveness, and some negotiate from an assessment of added benefit.

United States: ICER. ICER is an independent non-profit research organisation and should not be confused with the incremental cost-effectiveness ratio that shares its abbreviation. For every assessment it publishes a Health Benefit Price Benchmark: the prices, net of rebates and other concessions, that would reach thresholds of USD 100,000 to 150,000 per QALY and per equal value life year (evLY) gained. ICER notes that the top of the range is usually read as a ceiling price. It reports that a case could be made for a lower range of USD 50,000 to 100,000 but keeps the existing range, partly as an incentive for future innovation.

Sweden. The Dental and Pharmaceutical Benefits Agency (TLV) describes Sweden as using a value-based model for pricing new medicines: a product is reimbursed if TLV judges its cost reasonable in relation to the demonstrated health benefits, and a product with substantial benefit may have a high price regardless of its cost in other countries. TLV places this within an ethical platform set by the Swedish Parliament: human dignity, need and solidarity, and cost-effectiveness.

Germany. Since the AMNOG reform took effect on 1 January 2011, the Federal Joint Committee (G-BA) assesses the added benefit of a new medicine over an appropriate comparator, and the Central Federal Association of Health Insurance Funds then negotiates the reimbursement price with the manufacturer. If no agreement is reached, an arbitration board sets the price using European price levels. The link is to the extent of added benefit over the comparator rather than to a cost per QALY threshold.

Worked example: one medicine, three subgroups

All figures are illustrative. A new medicine is used in three subgroups. The threshold $k$ is GBP 30,000 per QALY, and every patient incurs GBP 2,000 of extra non-drug costs.

Step 1: value-based price per subgroup. Subgroup S1 has a value-based price of 30,000 × 1.0 − 2,000 = GBP 28,000. For S2, 30,000 × 0.6 − 2,000 = GBP 16,000. For S3, 30,000 × 0.3 − 2,000 = GBP 7,000.

Step 2: the menu of price and coverage. If the payer funds only subgroups where the medicine is cost-effective at the chosen price, each price buys a level of coverage. The net health benefit in a subgroup is the number of patients × ($P^{*}$ − price) / $k$.

At GBP 16,000, S1 contributes 400 × 12,000 / 30,000 = 160 QALYs. At GBP 7,000, S1 contributes 400 × 0.7 = 280 and S2 contributes 600 × 0.3 = 180, a total of 460.

Step 3: an average price. The total value is 400 × 28,000 + 600 × 16,000 + 1,000 × 7,000 = GBP 27.8 million. A single price that makes the medicine cost-effective on average over all 2,000 patients is 27.8 million / 2,000 = GBP 13,900. Net health benefit is +188 QALYs in S1 (400 × 14,100 / 30,000), +42 in S2 (600 × 2,100 / 30,000) and −230 in S3 (1,000 × −6,900 / 30,000), a total of zero.

Interpretation. Ignoring production costs, a revenue-maximising manufacturer on the menu picks GBP 16,000, and the NHS keeps 160 QALYs of net benefit. Under the average price, or separate subgroup prices of GBP 28,000, 16,000 and 7,000, revenue is GBP 27.8 million and the NHS gains nothing net. As Claxton, Sculpher and Carroll note, an average value-based price is equivalent to price discrimination and gives the manufacturer an incentive not to identify subgroups.

Boundaries with nearby concepts

Value-based pricing concerns the price of a product, while value-based purchasing adjusts payments to providers for quality or outcomes. External reference pricing sets prices from prices abroad. Value assessment and value-based assessment judge value, which may or may not feed a price. Indication-based and outcome-based pricing vary the price by use or by results. List and net prices are covered under drug pricing.

Criticisms and limits

Claxton, Sculpher and Carroll show that at the value-based price all the value of an innovation goes to the manufacturer during patent protection. The health system gains mainly after patent expiry, and only if generic prices fall and prescribing switches.

Dynamic efficiency. Danzon, Towse and Mestre-Ferrandiz argue that dynamic efficiency requires producers to capture the full social surplus from innovation. If each payer sets its threshold from its citizens' willingness to pay for health, manufacturers price to it and payers fund only patients for whom the drug is cost-effective at that price, they find prices roughly consistent with second-best static and dynamic efficiency. Claxton and colleagues warn that a single purchaser forcing prices below the value-based level could undermine confidence that investment returns can be realised, making research and development more costly. They add that the harm to innovation from the NHS declining to pay depends partly on the UK's share of the world market.

The threshold choice. The result is only as good as $k$. A threshold above the true opportunity cost lets prices displace more health than they add. ICER cites estimates of US health opportunity cost of about USD 30,000 to 40,000 and USD 104,000 per QALY, near or below the bottom of its benchmark range. The UK's 2026 increase, a government decision designed to improve the operating environment for pharmaceutical companies, raises the prices NICE can accept.

What counts as value. The QALY may miss benefits that matter, and attempts to add burden of illness and wider benefits proved contested in 2014. Prices also travel: TLV notes that a Swedish price may affect other markets through reference pricing, and that agreements with confidential net prices complicate international comparison.

Sources

• Claxton K, Sculpher M, Carroll S. Value-based pricing for pharmaceuticals: its role, specification and prospects in a newly devolved NHS. CHE Research Paper 60. Centre for Health Economics, University of York, February 2011. https://www.york.ac.uk/media/che/documents/papers/researchpapers/CHERP60_value_based_pricing_for_pharmaceuticals.pdf
• Danzon PM, Towse AK, Mestre-Ferrandiz J. Value-based differential pricing: efficient prices for drugs in a global context. NBER Working Paper 18593, December 2012. https://www.nber.org/papers/w18593
• Parliamentary Office of Science and Technology. Value Based Assessment of Drugs. POSTnote 487, January 2015. https://researchbriefings.files.parliament.uk/documents/POST-PN-487/POST-PN-487.pdf
• Department of Health and Social Care. 2024 voluntary scheme for branded medicines pricing, access and growth, May 2026 update. https://www.gov.uk/government/publications/2024-voluntary-scheme-for-branded-medicines-pricing-access-and-growth
• National Institute for Health and Care Excellence. NICE technology appraisal and highly specialised technologies guidance: the manual (PMG36), chapter 6, Committee recommendations. Published 31 January 2022, last updated 31 March 2026. https://www.nice.org.uk/process/pmg36/chapter/committee-recommendations
• National Institute for Health and Care Excellence. Changes to NICE's cost-effectiveness thresholds confirmed. News, 1 December 2025. https://www.nice.org.uk/news/articles/changes-to-nice-s-cost-effectiveness-thresholds-confirmed
• Institute for Clinical and Economic Review. 2023 Value Assessment Framework, updated 25 September 2023, with revisions to July 2026, sections 3.9 and 3.13. https://icer.org/wp-content/uploads/2025/12/ICER_2023_2026_VAF_070126.pdf
• Dental and Pharmaceutical Benefits Agency (TLV). International price comparison 2025. Reference 03747/2025. https://www.tlv.se/download/18.7da0ebe919bd8d1ee904a4de/1769772234825/international_price_comparison_2025.pdf
• Federal Joint Committee (G-BA). The benefit assessment of medicinal products in accordance with the German Social Code, Book Five (SGB V), section 35a. Web page, accessed 6 October 2026. https://www.g-ba.de/english/benefitassessment/